

Philippe Chadebech

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7543363/publications.pdf>

Version: 2024-02-01

22
papers

495
citations

932766

10
h-index

887659

17
g-index

23
all docs

23
docs citations

23
times ranked

581
citing authors

#	ARTICLE	IF	CITATIONS
1	Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. <i>Transfusion</i> , 2009, 49, 1785-1792.	0.8	102
2	Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. <i>American Journal of Hematology</i> , 2017, 92, 1340-1348.	2.0	85
3	Involvement of p21 in the PKC-induced regulation of the G2/M cell cycle transition. <i>FEBS Letters</i> , 1999, 444, 32-37.	1.3	66
4	Phosphorylation and Proteasome-Dependent Degradation of Bcl-2 in Mitotic-Arrested Cells after Microtubule Damage. <i>Biochemical and Biophysical Research Communications</i> , 1999, 262, 823-827.	1.0	57
5	Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. <i>American Journal of Hematology</i> , 2020, 95, 456-464.	2.0	46
6	IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and FcγRI. <i>Blood</i> , 2010, 116, 4141-4147.	0.6	40
7	Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. <i>International Journal of Cancer</i> , 2000, 87, 779-786.	2.3	36
8	Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. <i>American Journal of Hematology</i> , 2020, 95, 1235-1245.	2.0	18
9	Evidence of benefits from using fresh and cryopreserved blood to transfuse patients with acute sickle cell disease. <i>Transfusion</i> , 2016, 56, 1730-1738.	0.8	12
10	Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genotypical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404). <i>Contemporary Clinical Trials</i> , 2017, 62, 91-104.	0.8	11
11	Red blood cells for transfusion in patients with sepsis: respective roles of unit age and exposure to recipient plasma. <i>Transfusion</i> , 2017, 57, 1898-1904.	0.8	5
12	Ex Vivo Activation of Red Blood Cell Senescence by Plasma from Sickle-Cell Disease Patients: Correlation between Markers and Adhesion Consequences during Acute Disease Events. <i>Biomolecules</i> , 2021, 11, 963.	1.8	5
13	Clinical severity in adult warm autoimmune hemolytic anemia and its relationship to antibody specificity. <i>Haematologica</i> , 2018, 103, e35-e38.	1.7	3
14	New molecular basis associated with CD36 ⁺ negative phenotype in the Saharan African population. <i>Transfusion</i> , 2020, 60, 2482-2488.	0.8	3
15	Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions. <i>Cytokine</i> , 2020, 136, 155259.	1.4	2
16	Probability of TCD-Normalization in the "Drepagrefe" Trial Comparing Transplantation to Chronic Transfusion in Sickle Cell Anemia Children with Abnormal-Transcranial Doppler Is Associated with Lower Ang-2 and BDNF Plasma Levels. <i>Blood</i> , 2018, 132, 506-506.	0.6	2
17	Incidence and Risk of Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease Patients Based on a Prospective Study. <i>Blood</i> , 2016, 128, 95-95.	0.6	2
18	A Severe Case of Delayed Haemolytic Transfusion Reaction in a Sickle Cell Disease Patient: Immuno-Haematological Study, Cytokine Transcripts and Lymphocyte Subsets Analysis.. <i>Blood</i> , 2005, 106, 954-954.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Successful Administration of Rituximab To Prevent Recurrence of Delayed Haemolytic Transfusion Reaction Developed in a Sickle Cell Disease Patient.. Blood, 2007, 110, 2904-2904.	0.6	0
20	Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease Patients: Evidence of An Emerging Syndrome with Suicidal Erythrocyte Death. Blood, 2008, 112, 3037-3037.	0.6	0
21	Protective Effects of Carbon Monoxide Delivered By Corm-401 in Hyperhemolysis in Patients with Sickle Cell Disease. Blood, 2018, 132, 2367-2367.	0.6	0
22	Fetal Hemoglobin Measurement per Red Blood Cell Provides Biological and Clinical Protective Thresholds. Blood, 2019, 134, 1008-1008.	0.6	0